Treatment of secondary hyperparathyroidism in haemodialysis patients: A randomised clinical trial comparing paricalcitol and alfacalcidol

BMC Nephrology

Volumn 10, Issue 1, 2009, Pages

  Hansen, Ditte ^a   Brandi, Lisbet ^a,b   Rasmussen, Knud ^a,b  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; PARICALCITOL; VITAMIN D DERIVATIVE; 1-HYDROXYCHOLECALCIFEROL; ERGOCALCIFEROL; HYDROXYCOLECALCIFEROL;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENMARK; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FEMALE; MALE; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; ERGOCALCIFEROLS; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 70350035698     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-10-28     Document Type: Article

References (20)

1. Pathogenesis of secondary hyperparathyroidism. E Slatopolsky A Brown A Dusso, Kidney Int Suppl 1999 73 14 S19 10.1046/j.1523-1755.1999.07304.x 10633458
2. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. GA Block TE Hulbert-Shearon NW Levin FK Port, Am J Kidney Dis 1998 31 607 617 10.1053/ajkd.1998.v31.pm9531176 9531176
3. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. GA Block PS Klassen JM Lazarus N Ofsthun EG Lowrie GM Chertow, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307
4. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. SK Ganesh AG Stack NW Levin T Hulbert-Shearon FK Port, J Am Soc Nephrol 2001 12 2131 2138 11562412
5. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. SM Sprague E Lerma D McCormmick M Abraham D Batlle, Am J Kidney Dis 2001 38 51 S56 10.1053/ajkd.2001.28110 11689388
6. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. SM Sprague F Llach M Amdahl C Taccetta D Batlle, Kidney Int 2003 63 1483 1490 10.1046/j.1523-1755.2003.00878.x 12631365
7. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. AJ Brown J Finch E Slatopolsky, J Lab Clin Med 2002 139 279 284 10.1067/mlc.2002.122819 12032488
8. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. JL Finch AJ Brown E Slatopolsky, J Am Soc Nephrol 1999 10 980 985 10232683
9. 1-Hydroxy derivative of vitamin D 3: a highly potent analog of 1,25-dihydroxyvitamin D 3. MF Holick EJ Semmler HK Schnoes HF DeLuca, Science 1973 180 190 191 10.1126/science.180.4082.190 4348463
10. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. L Brandi M Egfjord K Olgaard, Nephrol Dial Transplant 2002 17 829 842 10.1093/ndt/17.5.829 11981071
11. 3on PTH secretion from bovine parathyroid glands. PK Nielsen, J Am Soc Nephrol 1997 8 578A
12. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 1 201 14520607
13. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. L Brandi H Daugaard PK Nielsen LT Jensen C Egsmose K Olgaard, Nephron 1996 74 89 103 10.1159/000189286 8883025
14. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. KJ Martin EA Gonzalez M Gellens LL Hamm H Abboud J Lindberg, J Am Soc Nephrol 1998 9 1427 1432 9697664
15. The Danish Society of Nephrology. Danish National Registry Annual Report 2007 http://www.nephrology.dk 10.1159/000168465
16. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. L Brandi H Daugaard E Tvedegaard PK Nielsen C Egsmose T Storm, et al. Am J Nephrol 1992 12 311 318 10.1046/j.1525-139X.2002.00086.x 1488999
17. Comparative review of the pharmacokinetics of vitamin D analogues. GR Bailie CA Johnson, Semin Dial 2002 15 352 357 10.1159/000083979 12358640
18. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays. L Brandi M Egfjord K Olgaard, Nephron Clin Pract 2005 99 128 c137 10.1053/ajkd.1998.v32.pm9808143 15722644
19. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. F Llach G Keshav MV Goldblat JS Lindberg R Sadler J Delmez, et al. Am J Kidney Dis 1998 32 48 S54 10.1097/01.ASN.0000133041.27682.A2 9808143
20. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. GA Block PS Klassen JM Lazarus N Ofsthun EG Lowrie GM Chertow, J Am Soc Nephrol 2004 15 2208 2218 15284307